Skip to content

Monoclonal antibodies as a treatment for Lassa virus

Monoclonal antibodies as a treatment for Lassa virus - Counteract

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53355
Enrollment
5
Registered
2023-04-24
Start date
2023-07-04
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lassa Virus Infection viral hemorrhagic fever

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Written informed consent to store samples and perform genetic testing. - Age >= 18 years - Individuals who have experienced PCR proven LASV infection and minimally 4 weeks post-infection

Exclusion criteria

Exclusion criteria: - Mental disorder that in the view of the investigator would interfere with adherence to the treatment or the study procedures, or the decision to participate in the study. - Immunosuppressive medication or other diseases associated with immunodeficiency.

Design outcomes

Primary

MeasureTime frame
Neutralization potency and breadth of monoclonal antibodies derived from LASV individuals who have recovered from LASV infection as assayed in neutralization assays using lentiviral vectors pseudo-typed with Lassa GP protein

Secondary

MeasureTime frame
- Percentage Lassa GP positive memory B cells as assayed by FACS (clonality) using Lassa GP protein labelled in different colors - Sequence screening of the most promising LASV monoclonal antibodies

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)